From listadm Fri Feb 13 05:53:19 2004 Received: from bgm-24-24-89-41.stny.rr.com (bgm-24-24-89-41.stny.rr.com [24.24.89.41]) by dkuug.dk (8.12.10/8.9.2) with SMTP id i1D4rBCm078990; Fri, 13 Feb 2004 05:53:16 +0100 (CET) (envelope-from JGTLPGJBDVQTUA@list.ru) Received: from [240.95.167.184] by 24.24.89.41 with HTTP; Thu, 12 Feb 2004 23:53:29 -0500 From: "Angelique Benitez" To: sc22jsg-request@dkuug.dk Subject: HEALTH CARE SECTOR: NEWS On Tubercin and FDA Testing--Sc22jsg-request 44333594 Mime-Version: 1.0 X-Mailer: plum Date: Thu, 12 Feb 2004 23:53:29 -0500 Reply-To: "Angelique Benitez" Content-Type: multipart/alternative; boundary="771624694657423" Message-Id: X-Spam-Score: 1.55 (*) HTML_MESSAGE,SUBJ_HAS_UNIQ_ID --771624694657423 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 8bit ambrosial strung worcester submit downpour coroner blemish beseech feel crusoe malignant conform cubic carcinoma carib cockpit algebra yard dante drake helena diploma chromosphere --771624694657423 Content-Type: text/html; charset=us-ascii Content-Transfer-Encoding: 8bit

Business Wire---Hard to Treat Diseases Incorporated - HTDS - Announces: Meeting with T-19 Manufacturer and Tubercin FDA Testing

Hard to Treat Diseases Incorporated (Pink Sheets: HTDS) announces that consultants of the Company are meeting with a P-3 manufacturer and an FDA testing group this week. It is expected that a decision will be made sometime this month regarding the most expeditious manner to safely make available T-19(R) to the people who need it.

HTDS consultants are also meeting with representatives of a prestigious FDA approved testing facility located at a major US University to discuss the protocols, procedures, budgets and cost estimates for additional testing. The testing results to date have been provided by Dr. Richard Ishmael, M.D. of The Natcel, Dev. and Cancer Treatment Center of Oklahoma and Dr. Wei R. Chen, Ph.D. of The University of Oklahoma. Such results are currently being reviewed by the Company's Scientific Advisory Panel.

HTDS consultants are also meeting with an FDA approved P-3 manufacturer regarding T-19(R). A P-3 manufacturer is capable of producing a product under extreme conditions. Tubercin(R) and the related T-19(R) are produced from live Tuberculosis cells under extremely stringent conditions. Depending on the approval process required by the testing facility and the opinion of the Company's Scientific Advisory Panel, the delivery system for the T-19 will either be a nasal spray or an inhaler.

"The holistic market for T-19(R) as an immunostimulant has phenomenal potential," stated the President and CEO of HTDS, Mr. Colm J. King. "We intend to get T-19(R) on the market as fast as possible. Additionally, the Company hopes to meet all criteria so that it may qualify Tubercin(R) for fast track treatment and thereby deliver it to patients in the near future. Results of the above meetings among the consultants will be released when available."

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no ob.ligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

dividend cow barnet avow addend emma israelite cuttlefish would becloud fastidious mig cladophora ajar workplace tome tropic optometry atropos barrel slog corporeal amethyst hightail chopin duffel antisemitism diadem airframe impermissible anterior avid refectory gilead dinnerware grandiloquent parish dame contrast family myosin bogota backlog refinery aldrich lightning hatfield kampala springtail archipelago cowpea accusation alfred alfresco botulism hijinks mbabane educable ambulant astigmat during sawfly antecedent truant assail fusiform mimi eastman psychoanalytic rampart integrand telemeter masonry brandt demo perseverance tectonic mcgovern rickets berkowitz sycamore connive bipartisan interest robin antigen breadfruit spontaneity risible reid captaincy rickettsia earthworm sclerotic judicatory matrimony biopsy mickey awe amoeba isomer eater memorable drapery decline weller puffin larkin cheesecloth smithfield dimple pantheon cottrell aspect baseboard drench cavalry loge amplitude depressant slapstick cautionary wiggly validate peephole relieve confine familism stoic mignon

--771624694657423--